Press Room

Press Release / Aug 03, 2007

Hovione’s sales grow 16%

Sales reach USD 93.7 million (EUR 70,2 million) for the fiscal year ended March 31st 2007

Loures, Portugal, July 31st - Hovione announced today that the consolidated sales for the fiscal year ended March 31st 2007 amounted to USD 93.7M, representing a growth of 16% over the previous year.

According to Hovione’s CEO, Guy Villax, “This was a year of strong sales growth despite the continued strengthening of the Euro. The main contribution to this growth came from the business segments in which Hovione has been strategically investing over the last few years. We have recently developed two new business segments: particle design services and formulation development services for inhalation – both technically challenging areas that have limited offer in the market.”

In 2006 Hovione invested approximately USD 12M in R&D, with 140 people working in R&D both in lab and pilot-scale. Hovione supported pharmaceutical research in Europe and in the USA, custom synthesizing the development of more than 40 different pharmaceutical ingredients used in clinical trials all over the world. Over the last 12 months, 7 new patent applications were filed as a result of the research conducted at Hovione.

Geographically, Hovione’s sales in the USA market represented 46% of our total sales (43% in 2005), Europe 30% (29%), Japan 15% (18%) and ROW 5% (5%).

“We face 2007 with optimism. Our goal for this year is very clear – surpass USD 100M. I am confident that we can reach this goal!”, adds Guy Villax.

 

About Hovione
Hovione is a world-class company dedicated to the process development and compliant manufacture of APIs for the Pharmaceutical Industry. With a 48-year track record in process development, quality standard and advanced particle design technologies, Hovione offers APIs for all drug delivery systems, from oral to injectable and from inhalation to topical applications. With FDA inspected plants in Europe and the Far East and a Technology Transfer Centre in New Jersey, no manufacturing partner is better positioned to support API development from gram scale to commercialization.

Also in the Press Room

See All

Every year, the largest bank in Portugal, Caixa Geral de Depósitos recognizes some of Portugal’s brightest young minds through the Caixa +Mundo Awards, providing nearly €800,000 in scholarships to students as they pursue higher education. In this year´s edition, Caixa named the award bestowed upon students pursuing science for Diane Villax. This prestigious honor places Diane Villax among the award’s namesakes – a distinguished group of prominent personalities who have made notable contributions to Portugal´s socio-economic, cultural, political and scientific development over the last 50 years, such as António Ramalho Eanes, Mário Soares, José Saramago, Sophia de Mello Breyner, Leonor Beleza, Elvira Fortunato, Rui Nabeiro, Américo Amorim, and José Manuel de Mello. Diane Villax will also honor the seven scientific award winners by personally meeting with each of them, and following their journeys as future innovators and leaders. But this honor is about far more than one individual. It is a celebration of an entire organization and the people behind it. For 67 years, generations of dedicated teams have worked together with passion, purpose, and excellence to manufacture life-saving medicines and advance science that has a real impact on people. This recognition belongs to all of us.    

News

Prestigious Caixa +Mundo Award named in honor of Diane Villax

May 14, 2026

CDMO Hovione and Industrial Design Consultancy (IDC) have announced that their new single-use capsule-based nasal delivery device is now available exclusively as part of an integrated platform that includes Hovione’s intranasal drug development and manufacturing services. The companies partnered in 2023 with plans for development of two capsule-based devices for intranasal delivery: the single-use device and a multidose device. Read the full article at OINDPnews.com      

Press Clipping
OINDP - Orally inhaled and nasal drug products news, May 11, 2026

Hovione and IDC announce new single-use capsule-based intranasal delivery device for dry powder formulations

May 11, 2026

Integrated approach simplifies development, reduces risk, and supports scalable manufacturing. Hovione and Industrial Design Consultancy Ltd.’s (IDC) lead single-use nasal dry powder device is now available for commercial partnerships. Hovione and IDC have completed the device design and established initial device manufacturing and supply capability, enabling pharmaceutical partners to leverage existing capsule filling infrastructure. This approach simplifies development, reduces cost and risk, and helps shorten timelines to the clinic and commercialization. “This milestone marks an important step in the evolution of our collaboration with IDC — from device innovation to a fully integrated intranasal drug delivery platform,” said Márcio Temtem, Ph.D., Vice President, Strategic Business Management, Hovione. “As the industry looks for faster, more reliable ways to bring complex therapies to patients, integration becomes critical. By bringing together nasal particle engineering science, formulation manufacturing and filling, and device technologies into a single offering, we enable a more seamless and predictable development journey, accelerating the path to market for intranasal therapies.” The nasal delivery device enables broad and targeted nasal deposition flexibility while delivering maximum usability and reliability. With a patented design and manufacturing process established, the platform is available for partnering with pharmaceutical companies on an exclusive basis as part of Hovione’s integrated offering for inhalation and nasal drug development and manufacturing. Additionally, IDC’s Managing Director, Stephen Knowles Ph.D., said the companies are now “well-advanced” with the development of a multi-use device to support an even wider range of therapies and patient needs. Read the full article at ContractPharma.com    

Press Clipping
Contract Pharma, 7 May 2026

Hovione, IDC Launch Intranasal Drug Delivery Platform

May 07, 2026

Also in Events

See All